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Lack of correlation of stem cell markers in
breast cancer stem cells
Y Liu1,4, R Nenutil2, M V Appleyard1, K Murray1, M Boylan1, A M Thompson1,3 and P J Coates*,1
1Dundee Cancer Centre, University of Dundee, Ninewells Hospital and Medical School, Dundee DD1 9SY, UK; 2Regional Centre
for Applied Molecular Oncology, Department of Oncological and Experimental Pathology, Masaryk Memorial Cancer Institute,
656 53 Brno, Czech Republic and 3Department of Surgical Oncology, MD Anderson Cancer Center, Houston, TX 77030, USA
Background: Various markers are used to identify the unique sub-population of breast cancer cells with stem cell properties.
Whether these markers are expressed in all breast cancers, identify the same population of cells, or equate to therapeutic
response is controversial.
Methods: We investigated the expression of multiple cancer stem cell markers in human breast cancer samples and cell lines
in vitro and in vivo, comparing across and within samples and relating expression with growth and therapeutic response to
doxorubicin, docetaxol and radiotherapy.
Results: CD24, CD44, ALDH and SOX2 expression, the ability to form mammospheres and side-population cells are variably
present in human cancers and cell lines. Each marker identifies a unique rather than common population of cancer cells. In vivo,
cells expressing these markers are not specifically localized to the presumptive stem cell niche at the tumour/stroma interface.
Repeated therapy does not consistently enrich cells expressing these markers, although ER-negative cells accumulate.
Conclusions: Commonly employed methods identify different cancer cell sub-populations with no consistent therapeutic
implications, rather than a single population of cells. The relationships of breast cancer stem cells to clinical parameters will
require identification of specific markers or panels for the individual cancer.
Current opinion proposes that tumours contain a sub-population
of cells with stem cell properties that are responsible for
maintaining tumour growth. These ‘cancer stem cells’ (CSCs) or
‘cancer-initiating cells’ are considered to have unlimited prolif-
erative potential and to divide slowly and asymmetrically, whereas
the resulting progenitor cells divide rapidly, progressively lose
proliferative potential and undergo limited differentiation to form
the heterogeneous populations of cells that are seen in tumours.
Although the hypothesis remains controversial (Lawson et al, 2009;
Rosen and Jordan, 2009), putative CSCs have been identified in
human cancers, including breast cancer, on the basis of the ability
of specific cell populations to initiate tumour formation when
transplanted into xenograft models. The clinically important
implication of the CSC hypothesis is that CSCs are critical
therapeutic targets, because they are uniquely able to reform the
tumour. Moreover, CSCs have been reported to exhibit enhanced
resistance to therapy through a variety of mechanisms (Bao et al,
2006; Phillips et al, 2006; Eyler and Rich, 2008; Lawson et al, 2009).
Therefore, identification of CSCs is important for understanding
tumour biology and should have clinical relevance.
Breast CSCs were first identified as a CD24 /low/CD44þ
population with enhanced ability to initiate tumour growth when
xenografted into immunocompromised mice (Al-Hajj et al, 2003).
Subsequent studies identified several other markers, such as
aldehyde dehydrogenase 1 (ALDH1), CD133, Sox2, CK5, alpha-6
integrin/CD49f, beta-1 integrin/CD29 or lack of estrogen receptor
(ER); cells exhibiting these phenotypes are also found in breast
cancer cell lines and may mark cells with enhanced tumour initiation
ability (Ginestier et al, 2007; Fillmore and Kuperwasser, 2008;
Wright et al, 2008; Charafe-Jauffret et al, 2009; Lawson et al, 2009;
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Kabos et al, 2011; Leis et al, 2012). Other markers for breast CSCs
include the identification of a side-population of cells that exclude
uptake of dyes due to the presence of membrane transporters, or
the ability to grow as anchorage-independent spheres (Christgen
et al, 2007; Engelmann et al, 2008; Grimshaw et al, 2008; Kok et al,
2009; Harrison et al, 2010).
Although the existence of a specific sub-population of cells with
stem cell or cancer-initiating properties and therapeutic resistance
has gained considerable support, conflicting data also exist
indicating that not all cancers contain a specific marker, or that
an individual marker necessarily associates with therapy resistance
or patient outcome (Kok et al, 2009; Stingl, 2009; Pajic et al, 2010;
Ahmed et al, 2012; Tan et al, 2013). Given the plethora of
approaches used to identify CSCs in different studies, the inter-
relationships of the identified cell populations with each other is
also unclear and might account for some of these discrepancies.
Therefore, to gain further insight into the nature of breast CSCs
and the inter-relationships of CSC markers with therapy response,
the aim of this study was to employ multiple methods to identify
breast CSCs in human samples and cell lines in vitro and in vivo,
and compare the expression of these markers with each other and
in relation to therapy.
MATERIALS AND METHODS
Human breast cancer samples. Metastatic deposits of 33 cancers
with axillary lymph node metastasis greater than 2mm in size (at
least pN1) were retrieved from the histopathological records of
consecutive ductal breast carcinoma cases diagnosed in Brno,
Czech Republic. All samples had been collected at surgery, fixed in
formalin and processed to paraffin wax for diagnostic histopathol-
ogy. The status of ER alpha, progesterone receptor and HER2 was
determined by immunohistochemistry (Table 1). HER2 gene
amplification status was confirmed by fluorescence in situ
hybridization according to the manufacturer’s instructions (Abbott
PathVysion HER2 DNA Probe Kit, Maidenhead, UK). Permission
for the use of human tissues was granted following local ethical
committee review and all patients gave consent for the use of their
tissue for research.
Cell culture and murine xenografts. The luminal-type human
breast cancer cell lines MCF7, T47D and ZR75-1 (steroid receptor
positive); SKBR3 (HER2þ ); and triple negative cell lines
MDAMB231 (mesenchymal) and MDAMB468 (epithelial, EGFRþ )
were obtained from ATCC, ECACC or DSMZ and grown in DMEM,
RPMI (for T47D) or McCoys 5A (for SKBR3) with 10% fetal bovine
serum (all from Invitrogen, Life Technologies Ltd., Paisley, UK) at
37 1C with 5% CO2. Cells were routinely passaged at least every three
days and all assays were performed when cells were sub-confluent.
For mammosphere culture, cells were plated in dishes previously
coated overnight with 1% poly(2-hydroxy-ethyl-methacrylate) in 90%
ethanol (Sigma, Poole, UK). Mammosphere growth medium
contained DMEM/F12 without serum but with B27 (Invitrogen)
and SingleQuots (Lonza Biologics, Slough, UK) as growth factor
supplements (Harrison et al, 2010). In some experiments, cells or
mammospheres were collected by centrifugation, fixed overnight in
formalin, re-suspended in agarose and processed into paraffin wax
using standard histological procedures. Colony-forming efficiencies
were measured by plating cells at low density depending on the cell
line and counting the number of colonies after growth for 12–15 days.
For xenografting, MCF7 or MDAMB468 cells were
re-suspended in a 50 : 50 mixture of culture medium and matrigel
(Becton–Dickinson) and injected subcutaneously into female
immunocompromised mice supplemented with slow release 17b-
estradiol pellets (for MCF7), as previously described (Appleyard
et al, 2012). Mice were housed under aseptic conditions in
individually ventilated cages. All animal procedures were carried
out under project licence 60/3405 after local ethical review and
according to the guidelines of the UKCCR.
Chemotherapy and radiotherapy in vitro and in vivo. Cultured
cells were treated three times with doxorubicin, docetaxel (Sigma-
Aldrich, Gillingham, UK) or ionizing radiation. For chemotherapy,
cells were exposed to the drug for 2 h, washed and incubated in a
fresh medium for 48 h, followed by two further rounds of
treatment. Cells were collected 48 h after the third treatment. For
ionizing radiation, cells were treated with a standard clinical
radiotherapy dose of 2Gy using a CIS Bio International 637
caesium irradiator (0.4Gymin 1). Radiation was repeated daily
for a total of three treatments and cells were collected 48 h after the
third exposure. Control cells were maintained under the same
conditions but without irradiation or exposure to chemotherapeu-
tic agents. In addition, established MCF7 xenografts were treated
with doxorubicin at the maximum tolerated dose once a week for
three weeks. Residual tumours were excised and fixed in 10%
neutral buffered formalin before processing to paraffin wax.
Immunohistochemistry. Cells grown on glass slides were fixed in
 20 1C acetone/methanol (1 : 1) for 10min at room temperature,
air-dried and stored at  80 1C. Sections of formalin-fixed
paraffin-embedded human breast cancer sample, cultured cell
pellets, spheroids or tumour xenografts were de-waxed and antigen
retrieval performed by boiling for 15min in citric acid buffer
(10mM, pH 6.0) in a microwave oven. Primary antibodies (Table 1)
were applied overnight at 4 1C and were detected with biotinylated
secondary antibody and avidin/biotinylated peroxidase complex
(Vector Laboratories Ltd., Peterborough, UK) with DAB (Sigma)
as chromogen. Nuclei were counterstained with haematoxylin. For
dual peroxidase staining, mouse and rabbit primary antibodies and
detection reagents were applied sequentially. The first antigen
was detected with DAB containing nickel sulphate to produce a
blue/grey reaction product and the second antigen was detected
with DAB (brown). These sections were mounted without
counterstaining.
Flow cytometry and FACS. Cells (106 in 1% bovine serum
albumin in PBS) were stained with FITC-conjugated mouse anti-
human CD44 and R-Phycoerythrin-conjugated mouse anti-human
CD24 (BD Bioscience, Oxford, UK) at 1/100 dilution at 4 1C for
30min. Aldehyde dehydrogenase activity was measured using the
ALDEFLUOR assay (STEMCELL Technologies, Grenoble, France).
Cells were incubated in ALDEFLUOR reagent with or without
DEAB (ALDH inhibitor) at 37 1C for 40min, centrifuged and re-
suspended in assay buffer. In some experiments, PE-conjugated
mouse anti-human CD24 (BD Bioscience, Oxford, UK) and Alexa
Fluor 647-CD44 (AbD Serotec, Kidlington, UK) were added.
Table 1. Antibodies used for immunohistochemistry
Antigen Supplier, clone/Cat # Dilution IHC
ALDH Becton–Dickinson, #611165 1/2000
CD44 Novocastra, NVL-CD44 1/4000
Sox2 Cell Signalling Technology #3579 1/200
EMA Dako, E29 1/5000
SMA Dako, 1A4 1/1500
ERa LabVision, SP2 1/500
PR LabVision SP2 1/2000
Abbreviations: ALDH¼ aldehyde dehydrogenase; CD¼ cluster of differentiation;
EMA¼ epithelial membrane antigen; ER¼ estrogen receptor; IHC¼ immunohistochemistry;
PR¼progesterone receptor; SMA¼ smooth muscle actin.
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For assessment of side-population, cells were stained with Hoechst
33342 (5 mgml 1) at 37 1C for 90min with or without reserpine
(10 mM, as a negative control; Sigma-Aldrich, Dorset, UK), washed
and re-suspended in PBS. CellQuest Pro (BD) and Summit v.4
(Dako, Glostrup, Denmark) software were applied for data
acquisition and analysis, respectively, using measurements from
10 000 cells in each experiment. Cells were sorted using a
FACSVantage (BD Bioscience) either directly into tissue culture
plates or into centrifuge tubes for further culture.
Statistical tests. For immunostaining, data were collected by
counting the percentages of positive cells in at least 10 high-power
fields. Student’s t-test was applied for cell culture assays, whereas
Mann–Whitney test was used for xenograft analyses due to uneven
distribution of positive cells in tumour material. All experimental
data were obtained from three experimental repeats and P-values
o0.05 were considered significant. Bar graphs show mean values
with 95% confidence intervals.
RESULTS
Variable expression and lack of correlation of CSC markers in
human breast cancers. To investigate the relationships of various
markers of the breast cancer stem cell population, we examined
axillary node metastatic deposits of primary cancer samples.
Immunohistochemistry showed highly variable levels of expression
of CD44, Sox2 and ALDH1 in different tumours; 27% of tumours
did not express CD44 in any tumour cells and the remaining
tumours showed up to 80% CD44þ cells; Sox2 was present in 73%
of tumours; and ALDH1þ tumour cells in only 43% of the
tumours studied (note that ALDH1 was commonly seen in stromal
cells, as previously reported (Resetkova et al, 2010) and CD44 was
expressed by a subset of lymphocytes (see Supplementary
Figure 1), but only tumour cells were included in this study). We
also observed a highly heterogeneous distribution of staining in
different areas of the section, where some areas containedB100%
of positive cells whereas other areas of the same section showed no
positive cells for a given marker (see Supplementary Figure 1 for an
example of SOX2 staining localized to a specific area of tumour
cells).
To investigate whether each of these markers was associated
with the same sub-population of cells, we employed double-
labelling immunohistochemistry on samples. Figure 1 shows three
different tumours, two of which contained cells positive for two of
the three markers and one that contained cells positive for all three
markers. Double labelling of the first two tumours showed that
individual cells expressed either one marker or the other, but not
both markers. In the third tumour, no co-localization of CD44 was
seen with either of the two other markers, ALDH1 or SOX2
(Figure 1). Thus, each marker identifies a unique sub-population of
cancer cells, rather than identifying the same population of cells.
Expression of CSC markers and CSC phenotypes in cell
lines. Given that the data from human cancers indicated that
the three CSC markers studies identified a unique rather than
common cell population, we investigated the relationships of
marker expression with other CSC phenotypes and with
#560 #3170 #5822
ALDH1
CD44
SOX2
ALDH1/CD44ALDH1/SOX2CD44/SOX2
CD44/SOX2
Figure 1. Marker expression and co-localization in human breast cancers. Immunocytochemistry of three different human breast cancers (#560,
#3170 and #5822). Single antigen detection of ALDH1, CD44 and SOX2 are shown for each cancer (positive reaction is brown, nuclei are
counterstained blue). Also shown are double labelling for the indicated antigens in each cancer using a black chromogen to identify one antigen
and brown for the second antigen, as indicated on the individual photomicrographs (no nuclear counterstain).
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therapeutic response in cell line models. FACS analysis of breast
cancer cell lines showed highly variable expression of CD44 and
CD24 in different cell lines (Figure 2a). MCF7 cells grown as
monolayers were strongly positive for CD24 with undetectable
CD44, MDAMB468 cells showed high level expression of both
markers and MDAMB231 cells expressed high levels of CD44 but
not CD24. When grown under mammosphere culture conditions,
only MCF7 and T47D of the cell lines tested formed three-
dimensional-structured spheroids, compared with the loosely
packed and irregular-shaped clusters formed by MDAMB468
and MDAMB231 cells in suspension (Figure 2b), as previously
reported (Rappa et al, 2008). To cross-correlate CD24/CD44
phenotypes in monolayer and suspension culture conditions, we
compared the representative population associated with each cell
line (i.e. changes in CD24 expression in MCF7, a change in the
CD24low/CD44high population in MDAMB468 and the CD44high
population in MDAMB231). MCF7 spheres showed a five-fold
increase in CD24high cells compared with cells grown as monolayer
(Figure 2c and d; P¼ 0.0268, n¼ 3) but no change in the CD24low
population. In MDAMB468, we demonstrated a four-fold
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Figure 2. CD24/CD44 expression in monolayer and mammosphere growth conditions. (A) FACS profiles of the indicated cell lines grown as
monolayers and stained for CD24 and CD44. (B) Photomicrographs of cells maintained under mammosphere growth conditions (bar¼100mm).
(C) FACS profiles of cells maintained under mammosphere growth conditions. (D) The percentages of cells with a CD24hi phenotype in MCF7 cells
grown as monolayers or mammospheres; of MDAMB468 monolayer or suspension cells with a CD24low/CD44hi phenotype; of the CD44high
population in MDAMB231 cells grown as monolayer or spheres. (E) Colony-forming efficiency (CFE) of FACS-sorted MCF7 or MDAMB468 cells on
the basis of CD24/CD44 expression, or of monolayers compared with cells growing under mammosphere culture conditions before plating.
Data are mean values with 95% confidence intervals; *Po0.05, n¼ 3.
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reduction of CD24low/CD44high cells in suspension cultures
compared with monolayers (Figure 2c and d; P¼ 0.015; n¼ 3)
and CD44 was decreased (P¼ 0.0103, n¼ 3) in MDAMB231 cells
growing in suspension culture conditions compared with mono-
layers (Figure 2c and d). There were no statistically significant
differences in colony-forming efficiencies of cells sorted according
to their CD24/CD44-expression profiles. Cells growing in suspen-
sion had reduced colony-forming efficiencies compared with cells
maintained as monoloayers (Figure 2e).
ALDH activity was highly variable in the cells tested, being
weaker in MCF7 cells compared with MDAMB468 (Figure 3a),
whereas all SKBR3 cells growing as a monolayer showed
substantial ALDH activity (data not shown). ALDEFLUOR-
positive and negative populations of MDAMB468 cells did not
show differential expression of either CD44 or CD24 (Figure 3b)
and did not have different cloning efficiencies (Figure 3c). The
percentage of cells with high ALDEFLUOR activity was three-fold
lower in MDAMB468 cells under suspension culture conditions
than in monolayers (Figure 3d), although this was not statistically
significant.
A typical side-population is identified as a tail-shaped tip
spreading out sideways from the main population, exhibiting low
fluorescent signal but relatively high blue/red signal ratio after
staining with Hoechst dye. None of the cell lines exhibited this
distinctive pattern (Figure 4), in agreement with published data
where a true SP was identified in only four of sixteen tested lines,
although a Hoechstlow population could be seen more often
(Christgen et al, 2007). In the absence of a true SP, we sorted the
Hoechstlow populations as used previously (Engelmann et al, 2008)
and measured the expression of CD44 and CD24. In MCF7, there
were no significant changes in expression of CD24 or CD44 in cells
with the lowest Hoechst fluorescence compared with unsorted cells
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Figure 3. ALDH activity and correlation with CD24/CD44 or colony-forming efficiency. (A) FACS profiles of ALDH activity in MCF7 and
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(Figure 4). In MDAMB468 cells, the Hoechstlow population
contained a higher proportion (10-fold increase) of cells with
low CD44 levels than the total population (Figure 4).
Expression of markers in xenografted cells. A number of studies
have indicated that CSCs, like normal stem cells, occupy a specific
niche within the tumour microenvironment, next to the stromal
interface. To investigate whether cells expressing putative CSC
markers showed such location preference and to investigate co-
expression of markers, immunohistochemistry was used to study
the expression of CD44, ALDH1 and Sox2 in xenografts. MCF7
xenografts did not express ALDH1, but expressed CD44 in
2.17±1.3% and Sox2 in 3.63±3.4% of cells. Double labelling
showed that Sox2 and CD44 were expressed in different cells,
rather than the same cell sub-population (Figure 5 top panel). Sox2
was not expressed in MDAMB468 xenografts, CD44 in
95.88þ 1.4% cells and ALDH in 8.47±7.6% of cells. Because
virtually all MDAMB468 tumour cells were CD44þ , ALDH1 was
expressed in a sub-population of these cells (Figure 5 bottom
panel). Cells expressing these markers were randomly distributed
in tumour xenografts and were not localized specifically at the
tumour/stroma interface (Figure 5).
Effects of therapy on marker expression. Monolayer cells were
exposed to three cycles of radiotherapy or chemotherapy. MCF7
cells that survived treatment with chemotherapy showed an
increase in the percentage of cells with low level CD24 expression
(Po0.05 for doxorubicin and Po0.01 for docetaxel), whereas
there was a non-statistically significant increase in the CD24hi
population following radiotherapy. The percentage of cells
CD44
CD44
Sox2
ALDH1
MCF7
MDAMB468
Figure 5. Marker expression and co-localization in tumor xenografts. Immunocytochemistry for CD44 and Sox2 in MCF7 xenografts and for
CD44 and ALDH1 in MDAMB468 xenografts as indicated. The image at the right-hand side of the two upper panels shows double staining of the
two markers with CD44 in black and the other marker in brown. Single-label staining is counterstained with haematoxylin; no counterstain has
been applied to double-labelled sections.
H
oe
ch
st
 b
lu
e
Hoechst red
CD
24
CD44
Unsorted
MCF7
MDAMB468
55.23% 42.14%
98.22% 96.49%
4.97% 93.27%
R2
R2
R6 R7
R5R4R4 R5
R7R6
256
192
128
64
0
256
192
128
64
0
256192128640
256192128640
FL
2-
H
104
103
102
101
100
104
103
102
101
100
FL
2-
H
104
103
102
101
100
104
103
102
101
100
103102101100
FL1-H
103102101100
FL1-H
104103102101100 104103102101100
Hoechstlow
Figure 4. Hoechstlow populations do not correlate with CD24/CD44 expression. Top panels represent data from MCF7 cells and the lower
panels are from MDAMB468 cells. The left column shows FACS profiles of Hoechst staining. Cells were sorted on the basis of low fluorescence
(gate R2) or were not sorted and analysed for CD24 and CD44 expression (middle and right panels).
BRITISH JOURNAL OF CANCER Variable cancer stem cell marker expression in breast cancer
2068 www.bjcancer.com |DOI:10.1038/bjc.2014.105
expressing CD44 was unchanged by any of the three treatments,
but both chemotherapeutic agents increased the percentage of ER-
negative cells (Po0.001 for each, Figure 6 upper panels). In
MDAMB468, there were non-statistically significant increases in
the percentages of cells with the CD24low/CD44high phenotype after
chemotherapy but not radiotherapy. The percentages of
MDAMB468 cells with ALDEFLUOR activity were not increased
after repeated chemotherapy exposures, and were decreased
following ionizing radiation (Po0.01) (Figure 6 lower panels).
DISCUSSION
This examination of putative CSC markers in breast cancer
demonstrated that individual markers are not always expressed in
an individual cancer, nor co-expressed in the same cells. We were
also unable to identify specific sub-populations in many cell lines
and found that relative expression levels of different markers
correlate neither with each other, nor with therapy resistance.
These data indicate that commonly used markers of the CSC sub-
population of breast cancer are not expressed in all tumours.
Although many studies have reported expression of individual
markers or marker combinations in association with various
clinical and biological characteristics, our data are supported by
previous observations that not all tumours or cell lines contain a
CD24 /low/CD44þ population (Sheridan et al, 2006; Grimshaw
et al, 2008; Wright et al, 2008; Hwang-Verslues et al, 2009; Park
et al, 2010) or contain cells that can form mammospheres (Farnie
et al, 2007; Grimshaw et al, 2008). Similarly, only a minority of
primary tumours and two-thirds of breast cancer cell lines have
any ALDH1þ cells, and a distinct SP is seen in only 25% of breast
cancer cell lines (Christgen et al, 2007; Tan et al, 2013). Further
evidence for divergent marker expression has come from
experimental studies, where individual murine breast cancers that
arise in a single model are marked by either CD133 expression or
the CD24low/CD44þ phenotype, but not both (Wright et al, 2008),
whereas CSCs in different models either express ITGB3 or do not
express this specific marker (Vaillant et al, 2008). However,
because these data are derived from either single markers or single-
model systems, the relationships between marker expression in
each situation has remained unclear. In the present study, we
comprehensively examined a number of different markers in a
range of primary material and cell lines and the data indicate that
none of the markers employed can be considered as a universal
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intervals, n¼ 3 for each. *Po0.05; **Po0.01.
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marker applicable to the identification of a CSC population in
breast cancer cell lines or metastatic breast cancer.
Secondly, by employing multiple methods in vitro, in vivo and
in human samples, we have shown that an individual cancer
commonly contains distinct cell populations expressing different
CSC markers. These data indicate that each marker identifies a
different cell sub-population, making the precise biology of each
population uncertain. Similar observations have been made in
more limited studies comparing expression of markers in specific
circumstances, such as a lack of correlation between CD24/CD44
populations and mammosphere forming ability (Grimshaw et al,
2008), the dye-excluding population and expression of either CD24
or CD44 (Zhou et al, 2007), and between CD44/CD24 and ALDH1
(Charafe-Jauffret et al, 2009; Stingl, 2009). Consideration of these
findings makes it unclear which of these populations, if any, are
authentic CSCs. In this regard, we were also able to investigate the
position of putative CSCs in vivo, on the basis that, similar to
normal stem cells, CSCs localize to the tumour/stroma interface
that forms the stem cell niche (Calabrese et al, 2007; Prince and
Ailles, 2008; Korkaya et al, 2011; Liu et al, 2011). However, we
found that CD44, Sox2 or ALDH1 cells are not localized
specifically to the stromal interface in either breast cancer
xenografts or human breast cancers.
Finally, a variable effect of therapy was demonstrated on
putative CSC populations in vitro. Although many studies have
indicated that CSCs are therapy-resistant, it has also been shown
that ERþ tumours with mammosphere gene expression profiles
have a better prognosis (Kok et al, 2009), whereas CD24 expression
is a marker of poor prognosis (Kristiansen et al, 2003; Ahmed et al,
2012). In different studies, expression of ALDH1 is not a predictor
of outcome (Tan et al, 2013), is not increased following treatment
(Resetkova et al, 2010), or ALDH1þ cells are enriched following
treatment but CD24/CD44 populations are not altered (Tanei et al,
2009). Similarly, although the CD24/CD49f population of murine
breast cancer has CSC properties, these cells are not therapy-
resistant (Pajic et al, 2010) and isolated CSCs from cell lines
commonly do not show enhanced radioresistance (Al-Assar et al,
2009; Kim et al, 2012). It is likely that at least some of these
discrepancies relate to the use of individual therapeutic regimes
associated with a single marker in different studies. In our work, we
applied repeated treatment to selectively remove the bulk of
tumour cells that are relatively therapy-sensitive and thereby
enrich for a therapy-resistant sub-population (Phillips et al, 2006;
Kabos et al, 2011), using three different treatments on two different
cell lines with different marker expression. We found that the two
cell lines tested show distinctive changes in CSC marker expression
according to the precise therapy employed. The only consistent
finding across therapeutic agents was an expansion of ER-negative
cells after exposure of the luminal cancer cell line, MCF7, to all
three therapies. These data support the observations that lack of ER
in individual cells in ERþ breast cancer is a marker of a therapy-
resistant population of CSCs (Kabos et al, 2011) and selection of
cells that will be unresponsive to endocrine therapy could account
for the delayed recurrence of initially ERþ breast cancer as ER
disease observed in clinical practice (Thompson et al, 2010;
Moussa et al, 2012).
In summary, these findings indicate that there are no universal
markers that identify a common breast CSC population or a
therapy-resistant population in all breast cancers, or even in a
given subtype of breast cancer. Taken together with the observa-
tions that CSC populations are highly dynamic and influenced by
their surrounding microenvironment (He et al, 2011; Korkaya et al,
2011; Scheel et al, 2011; Chaffer et al, 2013) the heterogeneity of
breast CSCs likely reflects the diversity of onocogenic events, cell of
origin and tumour microenvironmental factors operating in an
individual cancer. However, such diversity and plasticity of marker
expression makes it unlikely that there will be a simple relationship
between the identified CSC population and the clinical course of
breast cancer, accounting for the discrepant results often obtained
using marker approaches. It may therefore be more relevant to
focus on fundamental stem cell properties such as asymmetric
division or tumour initiation rather than expression of individual
markers as assessment methodology. In addition, the evidence for
plasticity of stem cell populations indicates that the measurement
of any CSC population, however defined, at a single point in time is
unlikely to have predictive therapeutic value.
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